{"groups":[{"description":"Zolinza (vorinostat) + CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)\n\nDoxorubicin: 50 mg/m\\^2 by vein/intravenous (IV) over 15 minutes on Day 1 of 21 day cycle\n\nPrednisone: 100 mg tablets by mouth/orally (PO) once a day on Days 1-5 of 21 day cycle\n\nZolinza (vorinostat): Phase I Starting dose of 300 mg by mouth each evening on Days 5-14 of 21 day cycle.\n\nCyclophosphamide: 750 mg/m\\^2 by vein over 1 hour on Day 1 of 21 day cycle\n\nVincristine : 1.4 mg/m\\^2 by vein over 15 minutes on Day 1 of 21 day cycle","id":"FG000","title":"Zolinza + CHOP"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"Toxicity"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"14"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"11"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"3"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"Recruitment Period: 04/03/09 to 12/19/12. All participants were recruited at The University of Texas (UT) MD Anderson Cancer Center."}